Gilead Sciences (NASDAQ:GILD - Get Free Report) was upgraded by equities researchers at Zacks Research from a "hold" rating to a "strong-buy" rating in a note issued to investors on Monday, Zacks reports. Zacks Research also issued estimates for Gilead Sciences' Q1 2027 earnings at $2.09 EPS, Q2 2027 earnings at $2.24 EPS, Q3 2027 earnings at $2.43 EPS, Q4 2027 earnings at $2.60 EPS and FY2027 earnings at $9.36 EPS.
Other equities research analysts also recently issued reports about the company. Wall Street Zen upgraded Gilead Sciences from a "hold" rating to a "buy" rating in a research report on Saturday, August 15th. HSBC raised Gilead Sciences from a "hold" rating to a "buy" rating and upped their price objective for the stock from $133.00 to $155.00 in a report on Monday, July 6th. Leerink Partners lowered shares of Gilead Sciences from an "outperform" rating to a "market perform" rating and cut their target price for the company from $146.00 to $127.00 in a report on Tuesday, July 21st. Truist Financial reduced their price target on shares of Gilead Sciences from $157.00 to $156.00 and set a "buy" rating on the stock in a research report on Tuesday, July 7th. Finally, Rothschild & Co Redburn lowered their price objective on shares of Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and five have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $158.04.
View Our Latest Research Report on Gilead Sciences
Gilead Sciences Price Performance
Shares of NASDAQ:GILD opened at $149.92 on Monday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The firm has a fifty day moving average price of $135.17 and a 200 day moving average price of $136.46. Gilead Sciences has a fifty-two week low of $108.46 and a fifty-two week high of $157.29. The firm has a market cap of $185.89 billion, a price-to-earnings ratio of -56.15 and a beta of 0.33.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating the consensus estimate of ($7.25) by $0.50. The company had revenue of $7.80 billion during the quarter, compared to analysts' expectations of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. Gilead Sciences's quarterly revenue was up 10.6% on a year-over-year basis. During the same period last year, the company posted $2.01 earnings per share. As a group, sell-side analysts expect that Gilead Sciences will post -0.47 earnings per share for the current fiscal year.
Insider Activity
In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction on Monday, August 17th. The shares were sold at an average price of $138.36, for a total transaction of $415,080.00. Following the completion of the transaction, the chief financial officer directly owned 165,646 shares of the company's stock, valued at $22,918,780.56. The trade was a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of the stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the completion of the sale, the director directly owned 12,894 shares in the company, valued at approximately $1,916,306.28. This represents a 58.26% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 90,000 shares of company stock worth $12,266,220. Company insiders own 0.30% of the company's stock.
Institutional Trading of Gilead Sciences
Institutional investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System lifted its stake in shares of Gilead Sciences by 12,498.3% during the 2nd quarter. California State Teachers Retirement System now owns 241,168,657 shares of the biopharmaceutical company's stock worth $30,469,248,000 after acquiring an additional 239,254,365 shares during the last quarter. BlackRock Inc. bought a new position in Gilead Sciences in the second quarter worth approximately $15,393,785,000. Norges Bank purchased a new position in Gilead Sciences during the 4th quarter worth $2,617,152,000. Legal & General Group Plc purchased a new position in Gilead Sciences during the 2nd quarter worth $1,316,606,000. Finally, Deutsche Bank AG bought a new stake in Gilead Sciences during the 2nd quarter valued at $918,387,000. Institutional investors own 83.67% of the company's stock.
More Gilead Sciences News
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: FDA approval expands HIV portfolio: The FDA approved Bixlenvo, Gilead’s once-daily, single-tablet regimen for virologically suppressed adults with HIV. The treatment could broaden Gilead’s offerings, particularly among underserved patients, and create an additional source of HIV revenue. FDA Approves Gilead's New Single Tablet HIV Regimen
- Positive Sentiment: Strong Buy ranking reinforces earnings optimism: Zacks upgraded Gilead to a Rank #1, or Strong Buy, citing improving earnings prospects. The upgrade may attract additional investor interest. Gilead Upgraded to Strong Buy
- Positive Sentiment: 2027 earnings estimates moved higher: Zacks raised its forecasts for every quarter in 2027 by $0.01 to $0.02 per share and increased its full-year estimate to $9.36 from $9.30. Erste Group also lifted its FY2027 estimate to $9.86 from $9.57. Although the revisions are modest, they indicate improving analyst expectations for Gilead’s earnings trajectory.
- Neutral Sentiment: Analyst support comes with limitations: Wall Street’s average recommendation remains favorable, but the accompanying analysis notes that sell-side ratings can be overly optimistic and may have limited predictive value. Investors will likely look for evidence that Bixlenvo gains meaningful market adoption.
- Neutral Sentiment: Stock near the upper end of its range: GILD is trading well above its 50-day and 200-day moving averages and close to its 52-week high, suggesting that considerable optimism may already be reflected in the valuation. This could limit near-term upside if product launches or earnings fail to exceed expectations.
Gilead Sciences Company Profile
(
Get Free Report)
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
